Aula sobre Trasplantes de Órganos Sólidos - Roche Trasplantes

Tratamiento y Prevención - Ponenciasnolate Mofetil reduces late renal allograft loss independent ofacute rejection. Transplantation 2000, 69: 2405-2409.18. M. Gonzalez Molina, D. Seron, R. Garcia del. Moral, M. Carreras,E. Sola, P. Gomez Ullate, L. Capdevila, M. A. Gentil.Protective effect of mycophenolate mofetil (MMF) against graftloss in patients with chronic allograft nephropathy (CAN). XCongress of the European Society for Organ Transplantation,ESOT 2001: pp 30 Abs 130.19. Skahan, B, Julian BA, Yves Vanrenterghem P, Neylan JN. Sirolimusreduces the incidence of acute rejection episodes despitelower cyclosporine doses in caucasian recipients of mismatchedprimary renal allografts: a phase II trial. Transplantation1999: 68: 10: 1526-1532.20. Opelz G. Influence of treatment with cyclosporine, azathioprineand steroids on chronic allograft failure . Kidney Int 1992;48(Suppl 52): S89-S92.21. Grinyo JM, Gil-Vernet S, Seron D, Cruzado JM, Moreso F, FulladosaX, Castelao AM, Torras J, Hooftman L, Alsina J. Steroidwithdrawal in mycophenolate mofetil- treated renal allograftrecipients. Transplantation 1997, 63: 1688-1690.22. Gjerstson DW. Survival trends in long.term first cadáver-donorkidney transplants, in Clinical Transplants 1991, edited byTerasaki PI, Cecka JM, Los Angeles, UCLA Tissue typing Laboratory,1991, p 225.23. Throgood J, van Houwelingen HC, van Rood JJ, Zantvoort FA,Schreuder GMT, Persijn GG: Long term results of kidney transplantationin Eurotransplant, in Organ Transplantation: LongTerm Results, edited by Paul LC, Solez K, New York, Basel,Hong Kong, Marcel Dekker, 1992, pp 33.24. Mayer AD, Dmitrewski J Squifflet JP, Besse et al. EuropeanTacrolimus multicenter renal study group. Multicenter randomizedtrial comparing tacrolimus (FK-506) and cyclosporinein the prevention of renal allograft rejection. Transplantation1997; 64: 436-443.25. D. Del Castillo. Analysis of primary and recurrent rejectionfollowing renal transplantation in a large, comparative, multicentretrial. Transplantation Proceedings 2001; 33:1259-1261.26 Knoll GA, Bell RC.Tacrolimus versus cyclosporine for immunosuppressionin renal transplantation: meta-analysis of randomizedtrials. BMJ 1999; 318:1104-1107.27. Gjerston DW, Cecka JM ,Terasaki PI: The relative effects ofFK-506 and cyclosporine on short and long term kidney graftsurvival. Transplantation1995; 60: 1384-1388.28. Suren N. Sehgal. Rapamune (RAPA, rapamycin, sirolimus):Mechanism of action Immunosuppressive effect results fromblockade of signal transduction and inhibition of cell cycle progression.1998; Clinical biochemistry, 31: 5: 335-340.29. Sousa JE, Costa MA, Abizaid A, Feres F, Pinto I, Seixas A, StaicoR, Mattos L, Sousa A, Falotico R, Jaeger J, Popma JJ, SerruysP: Lack of neointimal proliferation after implantation ofsirolimus-coated Stents in human coronary arteries. Circulation2001; 103: 192-195.30. Kahan BD, Podbielski J, Napoli KL. Immunosupressive effectsand safety of a sirolimus/cyclosporine combination regimen forrenal transplantation. Tansplantation 2998; 66: 1040-1046.31. Kries H, Cisterne JM, Land W. Sirolimus in association withmycofenolate mofetil induction for the prevention of acute graftrejection in renal allograft recipients. Transplantation 2000;89: 1252-1260.32. Cecka JM, Gjerston D, Teraski PI: Do prophylactic anti-limphocyteglobulins improve renal transplant survival in recipientand donor high-risk groups? Transplant Proc 1993; 25: 548-549.33. Opeltz G. Efficacy of rejection prophylaxis with OKT3 in renaltransplantation. Transplantation 1995, 60:1220-1224.34. Szczech LA, Berlin JA, Feldman HI. Anti-lymphocyte antibodyinduc therapy: The effect of antilymphocyte induction therapyon renal allograft survival: A meta-analysis of individual patientlevel data. Ann Intern Med 1998, 128: 817-826.35. Tran HT, Acharya MK, Mckay DB. Avoidance of cyclosporinein renal transplantation: effects of daclizumab, mycophenolatemofetil, and steroids. J Am Soc Nephrol 2000; 11: 1903-1909.36. Gjerston DW. A multi-factor analysis of kidney graft outcomesat one year and five years post-transplantation : 1996 UNOSupdate, in Clinical Transplants 1996. Edited by Cecka JM, TerasakiPI, Los Angeles UCLA Tissue Typing Laboratory, 1997;343.37. Terasaki PI, Gjerston DW, Cecka JM, Takemoto S, Cho YW.Significance of the donor age effect on kidney transplants. ClinTranspl 1977; 11: 366-372.38. Shoskes D, Cecka JM. Deleterious effects of delayed graft functionin cadaveric renal transplantation recipients independentof acute rejection. Transplantation 1998; 55: 1697-1701.39. Yokoyama I, Uchida K, Kobayashi T, et al. Effect of prolongeddelayed graft function on long-term graft outcome in cadaverickidney transplantation. Clin Transplant 1994; 8: 101.40. Almond PS, Matas A, Gilingham K, et al. Risk factors for chronicrejection in renal allograft recipients. Transplantation 1993;55: 752.41. Brenner BM, Cohen RA, Milford EL. In renal transplantation,one size may not fit all, J Am Soc Nephrol 1992; 3: 162.42. Mackenzie HS, Tulius SG, Heemann UW, et al. Nephron supplyis a major determinant of long-term renal allograft survival inrats, J Clin Invest 1994; 64: 2148.143